Analysis of the efficacy and safety of albumin-bound paclitaxel in first-line adjuvant chemotherapy for epithelial ovarian cancer
ZHANG Yu-hao
LI Jing
LIN Zhong-qiu
LU Huai-wu
Abstract：Objective To explore the efficacy and safety of albumin-bound paclitaxel combined with platinum-based agents as first-line adjuvant chemotherapy for epithelial ovarian cancer.Methods A total of 330 eligible patients with epithelial ovarian cancer who received initial treatment at the Gynecologic Oncology Department of Sun Yat-sen Memori-al Hospital,Sun Yat-sen University between January 25,2018 and September 28,2021 were enrolled in this study.These patients were retrospectively divided into two cohorts:Cohort 1(n=142),designated as the nab-paclitaxel group,and Cohort 2(n=188),designated as the paclitaxel group.The feasibility of nab-paclitaxel as a first-line treatment was compared and evaluated.Results No statistically significant difference was observed in median follow-up duration be-tween the nab-paclitaxel and paclitaxel groups(21.70 months vs.24.62 months,P=0.109).The median progression-free survival(PFS)did not differ significantly between the two groups(17.00 months vs.20.00 months,P=0.488).However,the nab-paclitaxel group demonstrated higher treatment feasibility(83.8％vs.69.1％,P=0.002)and a lower incidence of myelosuppression of varying degrees(73.2％vs.86.2％,P=0.003).Quality-of-life assessments revealed that the nab-pa-clitaxel group experienced milder gastrointestinal re-action,with statistical significance.Conclusion In the first-line adjuvant chemotherapy for epithelial ovarian cancer,albumin-bound paclitaxel+platinum may be used as an alternative regimen,especially for patients who are allergic to paclitaxel or have severe gastrointestinal reactions.
Keywords：epithelial ovarian canceralbumin-bound paclitaxelpaclitaxelfirst-line adjuvant chemotherapylife quality score
Publication Date：2025-09-02
Online Publishing Date：2025-10-20(First online date of this platform, not the publication date of the document)
Pages：5( 941-945 )